Want to see CLRB full AI Analyst Report?
CLRB Stock Chart & Stats
$2.54
$0.02(0.79%)
At close: 4:00 PM EDT
$2.54
$0.02(0.79%)
Day’s Range― - ―
52-Week Range$1.12 - $4.70
Previous CloseN/A
Volume9.26K
Average Volume (3M)121.35K
Market Cap
$10.59M
Enterprise Value$1.54M
Total Cash (Recent Filing)$33.99M
Total Debt (Recent Filing)$1.53M
Price to Earnings (P/E)―
Beta1.30
Next Earnings
Oct 29, 2026EPS Estimate
-0.56Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.56
Shares Outstanding9,452,108
10 Day Avg. Volume242,567
30 Day Avg. Volume121,346
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.78
Price to Sales (P/S)0.00
P/FCF Ratio-0.33
Enterprise Value/Market Cap0.15
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit14.02
Enterprise Value/Ebitda-0.07
Forecast
1Y Price Target
$10.00Price Target Upside293.70% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-2.17
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Durable Clinical EfficacyStrong response rates and durable benefit in late-line patients provide meaningful clinical validation for iopofosine I-131. If sustained in confirmatory testing, these results could support differentiation, regulatory progress, and eventual adoption in an underserved hematologic cancer setting.
Defined Regulatory PathwayThe company has moved beyond exploratory development toward a confirmatory Phase III program and a specified accelerated-approval objective. Breakthrough Designation and an anticipated six-month review could shorten the path from clinical validation to potential commercialization if execution remains on schedule.
Platform And Manufacturing ReadinessA validated phospholipid drug-conjugate platform and established manufacturing infrastructure could support more than one oncology program and facilitate scale-up after approval. Reported ligand stability and available finished-product capacity reduce the need to build these capabilities from scratch.
Bears Say
Pre-commercial LossesThe company remains pre-commercial and has no recurring product revenue to fund operations, while losses continue despite improvement from 2024. Until a therapy is approved and launched, future progress depends on clinical execution and access to external capital rather than internally generated earnings.
Persistent Cash BurnNegative operating and free cash flow show that the business is not self-funding its development programs. Continued spending on the confirmatory study and pipeline expansion can consume liquidity over the next several quarters, increasing dependence on financing before commercial revenue begins.
Milestone-dependent Financing And DilutionA substantial portion of the announced financing is conditional on execution and warrant-related criteria, so the full capital plan is not assured. The large warrant package also creates potential dilution, which may reduce the economic benefit to existing shareholders if exercised.
Cellectar Biosciences News
CLRB FAQ
What was Cellectar Biosciences’s price range in the past 12 months?
Cellectar Biosciences lowest stock price was $1.12 and its highest was $4.70 in the past 12 months.
What is Cellectar Biosciences’s market cap?
Cellectar Biosciences’s market cap is $10.59M.
When is Cellectar Biosciences’s upcoming earnings report date?
Cellectar Biosciences’s upcoming earnings report date is Oct 29, 2026 which is in 8 days.
How were Cellectar Biosciences’s earnings last quarter?
Cellectar Biosciences released its earnings results on Aug 13, 2026. The company reported -$0.57 earnings per share for the quarter, missing the consensus estimate of -$0.52 by -$0.05.
Is Cellectar Biosciences overvalued?
According to Wall Street analysts Cellectar Biosciences’s price is currently Undervalued.
Does Cellectar Biosciences pay dividends?
Cellectar Biosciences does not currently pay dividends.
What is Cellectar Biosciences’s EPS estimate?
Cellectar Biosciences’s EPS estimate is -0.56.
How many shares outstanding does Cellectar Biosciences have?
Cellectar Biosciences has 9,452,108 shares outstanding.
What happened to Cellectar Biosciences’s price movement after its last earnings report?
Cellectar Biosciences reported an EPS of -$0.57 in its last earnings report, missing expectations of -$0.52. Following the earnings report the stock price went down -4.615%.
Which hedge fund is a major shareholder of Cellectar Biosciences?
Currently, no hedge funds are holding shares in CLRB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cellectar Biosciences
Cellectar Biosciences is a biopharmaceutical firm engaged in the research, development, and market introduction of therapeutic agents to combat cancer. The company's primary asset is CLR 131 (iopofosine I-131), a phospholipid drug conjugate (PDC), which is currently undergoing several clinical evaluations. It is in Phase 2 clinical trials for individuals with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies. Additionally, CLR 131 is being studied in Phase 2B for r/r multiple myeloma (MM) and in Phase I trials targeting a range of pediatric cancers, r/r head and neck cancers, and R/R MM. Furthermore, Cellectar is advancing CLR 1900, another PDC-based chemotherapeutic program, which is in preclinical stages with the aim of treating solid tumors. The firm also participates in collaborative PDC development initiatives with partners such as Avicenna Oncology GMBH for the CLR 2000 Series, Orano Med for the CLR 12120 Series, as well as IntoCell Inc. and LegoChemBio. Established in 2002, Cellectar Biosciences maintains its corporate headquarters in Florham Park, New Jersey.
CLRB Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong clinical validation for iopofosine (durable responses and high response rates including a near-80% major response in the BTKi-exposed subgroup), clear progress toward a confirmatory Phase III and an intended accelerated approval filing in 1H 2027, plus meaningful balance-sheet reinforcement from an oversubscribed financing. The company is also advancing CLR 125 and expanding its PDC platform with supporting peer-reviewed data and manufacturing readiness. Offsetting these positives are materially higher R&D costs, a wider net loss in dollar terms, timing and operational risks tied to site activation/IRB/radiopharmacy readiness, just-in-time isotope production complexities, actinium-225 supply risk for alpha programs, and potential dilution from issued warrants. Overall, the highlights (clinical data, regulatory path, financing, pipeline expansion and manufacturing preparedness) materially outweigh the operational and financing caveats.View all CLRB earnings summariesCLRB Stock 12 Month Forecast
Average Price Target
$10.00
▲(293.70% Upside)
Technical Analysis
Ownership Overview
0.97% Insiders
1.16% Mutual Funds
23.18% Other Institutional Investors
71.40% Public Companies and
Individual Investors